10-K · March 16, 2026
WW positions itself as the integrated destination for weight management in the GLP-1 era, combining its six-decade community/behavioral platform with a U.S. clinical offering that provides access to GLP-1 medications.…
Earnings analysis · 10-Q
Filed May 7, 2026 · Our reading of the company's report
The latest report
WW International reported Q1 2026 results with revenue of $168.3 million, down 9.6% from $185.2 million year-over-year, and a diluted EPS loss of $5.20, which dramatically missed estimates of a loss of $2.07. Key growth…
WW International reported Q1 2026 results with revenue of $168.3 million, down 9.6% from $185.2 million year-over-year, and a diluted EPS loss of $5.20, which dramatically missed estimates of a loss of $2.07. Key growth in Clinical Subscription Revenue (+31.8% YOY) was overshadowed by significant declines in Behavioral Revenue (-17.5% YOY), amid ongoing difficulties in subscriber growth and operational efficiency challenges.
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Q1 2026 revenue was $168.3 million, down 9.6% from $186.6 million in Q1 2025.
Clinical Subscription Revenue rose 31.8%, from $29.5 million in Q1 2025 to $38.8 million in Q1 2026.
Marketing expenses surged to $92.9 million in Q1 2026, compared to $78.8 million in Q1 2025.
Interest expense decreased to $11.5 million in Q1 2026, down from $27.6 million in Q1 2025.
End of Period Subscribers fell by 22.6% from 3,434.1K in Q1 2025 to 2,659.2K in Q1 2026.
Gross margin fell to 70.5% in Q1 2026 from 71.2% in Q1 2025.
Net loss for Q1 2026 was $52.0 million, compared to $72.6 million in Q1 2025, indicating ongoing financial distress.
Total subscribers decreased by 17.2%, from 3,335.7K in Q1 2025 to 2,760.8K in Q1 2026, impacting profitability.
Operational reliance on technology raises risks of service disruptions affecting future revenue and brand perception.
Reaffirms financial guidance for FY 2026, projecting revenue between $620 million and $635 million.
WW positions itself as the integrated destination for weight management in the GLP-1 era, combining its six-decade community/behavioral platform with a U.S. clinical offering that provides access to GLP-1 medications.…
WW reported revenues of $172,091,000 in the three months ended September 30, 2025, down $20,796,000 (10.8%) versus $192,887,000 in the prior-year quarter, but delivered a positive operating income of $8,035,000 versus…
WW reported quarterly revenue of $202,073,000 and diluted EPS of $0.29 for the three months ended June 29, 2024. Gross margin expanded to 67.9% and the company returned to operating income of $35,933,000 in Q2, although…
WW reported net revenue of $206,548,000 for the three months ended March 30, 2024 and a net loss of $347,902,000 (diluted loss per share $4.39). Gross profit expanded to $137,800,000 (66.7% gross margin), but the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.